Simply Oncology

Send us Fan Mail

Join us as we discuss all things prostate radiotherapy with Dr Alison Tree. 
Alison is synonymous with all things prostate radiotherapy and is superb at setting the scene for prostate cancer.

Based at The Royal Marsden Hospital, and The Institute of Cancer Research, Dr Tree has played a key role in several major prostate radiotherapy trials. These include working alongside Professor Nicholas Van As in the PACE trial portfolio and also working on the PIVOTAL Boost trial.

She has special interest in MR-guided prostate radiotherapy (the PRISM trial), boosting dominant intra-prostatic lesions (the DELINEATE trial) and hypofractionation in prostate cancer.

Alison Tree is an amazing speaker on the subject of prostate radiotherapy and we are sure this will be of of interest to anyone interested in prostate cancer or radiotherapy.

This episode contains everything we could want to know about the current position of prostate radiotherapy and future directions of travel.

Enjoy

Send us Fan Mail

Join us for part 2 of our excellent review of high grade brain tumours with Professor Anthony Chalmers.
We look at the role of PARPi and the challenges with new therapies in high grade gliomas.
We discuss tumour treatment fields, vaccine trials and immunotherapy in brain tumours.
We also hear Prof Chalmers wish list for helping advance research in brain tumours.
We hope you enjoy!

Send us Fan Mail

Join us today as we discuss high grade brain tumours with internationally recognised expert Professor Anthony Chalmers.
Part 1 of 2 and we discuss implications of new molecular profiling on prognosis and treatment options in high grade brain tumours.
We look at some recent changes in radiotherapy volumes and doses in brain tumours.
We also discuss challenges in treatment of high grade brain tumours and the impact of steroids in high grade brain tumours alongside surgery, chemotherapy and radiotherapy.

Send us Fan Mail

This week the Simply Oncology podcast goes global!

Over 80 % of the world population is living in low or middle income countries.

In this podcast, we're hopefully going to try and cover what is global oncology, what some of the challenges that low middle income countries are facing in terms of delivering cancer care.
We also touch on how clinicians in the UK might be able to cooperate and contribute to improving Cancer care globally, and to do this, we are delighted to welcome Dr Susie Stanway to the podcast. 

The scale if the issues is HUGE and Susie talks us through some thoughts on what may help and how we can get involved.

A truly humbling episode

John & Mike

Send us Fan Mail

Join us for our second discussion with Professor Alison Birtle on metastatic prostate cancer.
This time we look at mCRPC. What are our choices after first line therapy.
We discuss;
-PARPi and BRCA testing
-Docetaxel re-challenge
-Cabazitaxel
-Patient Support

This is a real tour de force by Alison.
We hope you enjoy.
John & Mike

Send us Fan Mail

Join us as we discuss the frontline therapy of metastatic hormone sensitive  prostate cancer with Professor Alison Birtle.
Alison has been involved in many of the key trials in urological cancers and shares her take on selecting patients for triplet therapy.
We also look at the factors that affect treatment choices for our mHSPC pateints.
This area has changed so much in recent years and Alison brings those changes to life in this episode.

You hope you enjoy!
John & Mike

Send us Fan Mail

Join us in this episode where we look at the treatment landscape in ovarian cancer.
We talk to Dr Shibani Nicum and Dr Rebecca Bowen who both specialise in the treatment of ovarian cancer.
They both lead the UK Gynae Trials Group (GTG) group and are involved in running the excellent UK Gynae-oncology Meeting (UKGOM).
We look at the use of PARPi, Bevacizumab (Avastin) and new targets in ovarian cancer.

This is a rapidly changing environment and this is an excellent overview by Shibani and Rebecca.

We hope you enjoy.

John & Mike

ps- With exclusive update on the date of next years UKGOM meeting

Send us Fan Mail

Join us as we talk with Benson Fayehun, a passionate advocate for addressing health inequalities. Benson is the Founder and President of the Relief for Human Suffering Foundation, a U.S.-based public charity, and the UK Head of Oncology Business Unit at MSD*.

In this episode, we delve into how factors like poverty, socio-economic status, language, and more often have a greater impact on cancer care outcomes than the treatment itself.

This thought-provoking conversation highlights some of the systemic challenges in healthcare and opens the door to critical themes we plan to revisit in future episodes.

We hope you enjoy.

John & Mike

* This is not a MSD endorsement and we acknowledge that many pharma companies are interested in this area.
This episode is not sponsored by MSD.

Send us Fan Mail

After a great overview of cervical cancer highlights we now go back to gynae cancer specialist Dr Gemma Emminowicz for insight on endometrial cancer highlights.

KEYNOTE B21- looking at adding pembrolizuamb in the adjuvant setting

DUO-E - looking at durvalumab and olaparib in the metastatic setting

The horizon for antibody drug conjugates in endometrial cancer.

We hope you enjoy

John& Mike

Send us Fan Mail

We talk again to Gynae-oncology specialist  - the excellent -Dr Gemma Eminowicz from UCL hospital. Gemma also played a key role supporting Dr Mary McCormack in delivering the INTERLACE trial.

We talk about updates from ESMO and IGCS on cervical cancer.
Gemma discusses her Quality of Life data she presented from INTERLACE and of course we discuss the exciting KEYNOTE A18 data.

We hope you enjoy.

John & Mike